Drug makers win Medicaid pricing carve-out disguised as outcome-based reform
S. 1637 — MVP Act · Filed by Markwayne Mullin (R-OK) · 2 cosponsors · Introduced May 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicaid and Medicare law to codify and expand 'value-based purchasing arrangements' (VBPs)—deals where drug manufacturers offer discounts or rebates tied to whether patients achieve specific health outcomes. The bill allows manufacturers to report multiple prices for the same drug under VBPs, excludes outcome-based rebates from price calculations used to set Medicaid rebates, and carves out VBP payments from federal anti-kickback rules. The primary beneficiaries are pharmaceutical manufacturers, who gain pricing flexibility and reduced rebate obligations; the bill's stated intent is to encourage outcome-focused drug pricing, but the mechanism shifts negotiating power away from Medicaid and toward manufacturers.
Why we flagged it
The bill's operative mechanism—excluding outcome-based rebates from Medicaid price calculations, permitting multiple best-price reporting, and carving VBPs out of anti-kickback enforcement—functions as a targeted pricing relief for drug manufacturers. The 'value-based' framing obscures that the primary effect is to reduce Medicaid's negotiating leverage and rebate recovery.
What the text implies
- By allowing manufacturers to exclude outcome-based rebates from average manufacturer price (AMP) calculations, the bill reduces the baseline price used to compute mandatory Medicaid rebates, lowering rebate amounts owed to states and the federal government—a direct transfer of savings from public programs to manufacturers.
- The anti-kickback exception (Section 5) permits manufacturers to make payments to states when patients fail to achieve outcomes, creating a financial incentive structure that may discourage states from enrolling high-risk or sicker patients in VBPs, potentially concentrating access among healthier populations.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers (especially those with specialty/high-cost drugs); biologics manufacturers; drug companies with rare-disease or gene-therapy portfolios